Nanomedicine

Ashvattha Therapeutics Announces First Patient Enrolled in Expanded Phase 1/2 Study of Imaging Agent 18F-OP-801 in Additional Neurological Indications

Retrieved on: 
Thursday, February 22, 2024

The study will evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of 18F-OP-801 in patients with amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple sclerosis (MS) and Parkinson’s disease (PD).

Key Points: 
  • The study will evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of 18F-OP-801 in patients with amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), multiple sclerosis (MS) and Parkinson’s disease (PD).
  • “This study builds on preclinical data which demonstrated 18F-OP-801's ability to cross the blood-brain barrier and be taken up by activated microglia in regions of neuroinflammation in multiple disease models.
  • Additional objectives include determining the correlation between PET imaging signal, biomarkers of disease activity and clinical disease assessments.
  • The study will also assess test/retest repeatability of 18F-OP-801 uptake in a subset of subjects.

A faster, more efficient imaging system for nanoparticles

Retrieved on: 
Tuesday, January 30, 2024

A new technique developed at INRS pushes back some of the limits of the infrared imaging of rare-earth doped nanoparticles.

Key Points: 
  • A new technique developed at INRS pushes back some of the limits of the infrared imaging of rare-earth doped nanoparticles.
  • It consists of a high-precision, short-wave infrared imaging technique capable of capturing the photoluminescence lifetimes of rare-earth doped nanoparticles in the micro- to millisecond range.
  • What's more, the photoluminescence lifetime of nanoparticles doped with these ions has the advantage of being minimally affected by external conditions.
  • Finally, in fundamental science, these unprecedented results will allow scientists to synthesize rare-earth nanoparticles with even more interesting optical properties.

Global Nanotechnology Market Poised to Reach $183.7 Billion by 2028, According to BCC Research Analysis

Retrieved on: 
Thursday, January 11, 2024

BOSTON, Jan. 11, 2024 /PRNewswire/ -- The global nanotechnology market is experiencing robust growth, propelled by continuous advancements in science and technology that enable the manipulation of matter at the nanoscale. This market, characterized by the development, production, and commercialization of nanotechnology-based products, has witnessed widespread applications across diverse industries. Nanomaterials, including nanoparticles and nanostructured materials, serve as the building blocks for innovations in electronics, healthcare, energy, and materials science. Specialized nanotools and instruments, such as scanning probe microscopes and electron microscopes, facilitate the study and manipulation of materials at the nanoscale. Nanodevices, ranging from Nanosensors to nanomedicine solutions, showcase the transformative potential of nanotechnology. Government initiatives, increased research and development activities, and collaborations between academia and industry contribute to the market's growth. Despite challenges related to regulation and public perception, the outlook for the global nanotechnology market remains promising, driven by ongoing technological breakthroughs and the integration of nanotechnology into a myriad of applications.

Key Points: 
  • According to the latest BCC Research study, the demand for Global Nanotechnology Market is estimated to increase from $68.0 billion in 2023 to reach $183.7 billion by 2028, at a compound annual growth rate (CAGR) of 22.0% from 2023 through 2028.
  • Despite challenges related to regulation and public perception, the outlook for the global nanotechnology market remains promising, driven by ongoing technological breakthroughs and the integration of nanotechnology into a myriad of applications.
  • This report delves into the nanotechnology industry , offering comprehensive estimates and forecasts for the global market.
  • The report narrows its attention to the global nanotechnology market, categorizing it by types such as Nanosensors, nanodevices, and nanomaterials, among others.

Ashvattha Therapeutics Announces the Appointment of Mehdi Paborji as Senior Vice President of Technical Operations

Retrieved on: 
Thursday, January 4, 2024

REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations.
  • Dr. Paborji will oversee technical operations, CMC, and manufacturing of the Company’s nanomedicine pipeline.
  • We look forward to leveraging Dr. Paborji’s expertise to support these efforts and successfully execute on our product development timelines.”
    Dr. Paborji joins Ashvattha from Rain Oncology, where he served as the Senior Vice President of Technical Operations and CMC.
  • Previously, he was Chief Technical Officer for Valorum Biologics, Vice President of Technical Operations and CMC at Sunesis Pharmaceuticals (acquired by Viracta Therapeutics), and Chief Operating Officer for both Biotie Therapies (acquired by Acorda Therapeutics) and TheraVida.

Ashvattha Therapeutics to Participate in Upcoming Ophthalmology Conferences

Retrieved on: 
Monday, November 20, 2023

REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences.
  • Ashvattha’s Co-Founder, President, and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings.
  • If you are interested in a meeting, please contact your BTIG representative.

ViaNautis Bio announces $25 million Series A financing to drive the next generation of genetic nanomedicines

Retrieved on: 
Monday, November 13, 2023

Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.

Key Points: 
  • Formerly known as SomaServe, ViaNautis has secured support from a consortium of prominent global investors enabling the advancement of its proprietary drug delivery platform – polyNaut®.
  • ViaNautis’s polyNaut® platform applies advanced polymer materials and in silico screening to precisely guide genetic molecules such as pDNA, mRNA, siRNA and ASOs to their intended targets.
  • ViaNautis presents an excellent opportunity in the world of genetic therapies by enabling the delivery of cargoes to otherwise inaccessible sites of action in the body.
  • It opens a plethora of novel prospects in the world of genetic therapies, offering the ability to reach previously inaccessible treatment sites.

Ashvattha Therapeutics Announces First Patient Dosed via Subcutaneous Administration of Anti-Angiogenic Therapeutic D-4517.2 for Wet AMD and DME in Phase 2 Chronic Dosing Study

Retrieved on: 
Wednesday, November 1, 2023

The open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet AMD and DME.

Key Points: 
  • The open-label study will evaluate the safety and efficacy of chronic D-4517.2 dosing in patients with wet AMD and DME.
  • “This study marks a significant step forward in advancing D-4517.2 as an at-home, maintenance treatment option for patients with wet AMD and DME.
  • Following the return of fluid to baseline levels, subjects will be concurrently dosed with both aflibercept and D-4517.2.
  • The initiation of the Phase 2 chronic dosing study is supported by results from Phase 1 and Phase 2 single dose studies that demonstrated good safety and tolerability of D-4517.2.

Ashvattha Therapeutics Announces Appointment of Dr. Sakura Minami as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations

Retrieved on: 
Monday, October 9, 2023

REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head of Clinical Operations.
  • Ms. Thayer has more than 20 years of progressive leadership experience in clinical development operations across various therapeutic areas from Phase 1 through Phase 3.
  • She previously served as Vice President, Head of Clinical Operations at Recode Therapeutics where she established the clinical operations function at the company.
  • Prior to Recode, she led clinical operations at Global Blood Therapeutics (Pfizer), StemCells Inc, FivePrime Therapeutics (Amgen), CV Therapeutics (Gilead), Titan Pharmaceuticals and Becton Dickinson Immunocytometry Systems.

Mana.bio Advances AI-Based Lipid Nanoparticle (LNP) Platform to Accelerate "Programmable Drug Delivery" for RNA and Gene Therapies

Retrieved on: 
Tuesday, October 10, 2023

Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.

Key Points: 
  • Mana.bio's integrated experimental and machine learning platform enables the discovery of smarter, faster, more precise delivery formulations to unlock the field of nucleic acid-based and genetic medicines.
  • We are encouraged by our platform's early in vivo success and for its potential to deliver breakthrough therapies for a broad range of diseases."
  • RNA-based therapies and genetic medicines offer immense potential to transform approaches to vaccines, gene editing, gene therapy and more.
  • The limitations on delivery methods have severely restricted the full therapeutic promise of RNA, CRISPR and gene therapies.

Pharmaceuticals Top Trending Markets - By The Business Research Company

Retrieved on: 
Monday, September 11, 2023

LONDON, Sept. 11, 2023 /PRNewswire/ -- As per The Business Research Company's analysis, the pharmaceuticals market is poised for substantial growth in the coming years, with projections indicating a remarkable trajectory. It is anticipated that the market will surge to $2,050 billion by 2025 and further escalate to a staggering $3,206 billion by the year 2030. This dynamic expansion is attributed to various factors, including advancements in healthcare technologies, increasing global healthcare expenditures, and the growing prevalence of chronic diseases, all of which drive demand for pharmaceutical products and services.

Key Points: 
  • In this thriving pharmaceutical landscape, business intelligence and market insights play a pivotal role in guiding companies towards informed decision-making.
  • Reports from The Business Research Company (TBRC) offer invaluable assistance to businesses within the pharmaceuticals industry.
  • Interested to know more about The Business Research Company?
  • The Business Research Company has published over 6500+ detailed industry reports, spanning over 3000+ market segments and 60 geographies.